- Home
- OBIO vs ACRV Comparison
OBIO vs ACRV Comparison
Compare OBIO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ACRV
- Stock Information
- Founded
- OBIO 2017
- ACRV 2018
- Country
- OBIO United States
- ACRV United States
- Employees
- OBIO N/A
- ACRV N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- OBIO Health Care
- ACRV Health Care
- Exchange
- OBIO Nasdaq
- ACRV Nasdaq
- Market Cap
- OBIO 198.2M
- ACRV 189.0M
- IPO Year
- OBIO N/A
- ACRV 2022
- Fundamental
- Price
- OBIO $4.72
- ACRV $5.54
- Analyst Decision
- OBIO Strong Buy
- ACRV Strong Buy
- Analyst Count
- OBIO 4
- ACRV 6
- Target Price
- OBIO $16.25
- ACRV $22.40
- AVG Volume (30 Days)
- OBIO 50.3K
- ACRV 69.3K
- Earning Date
- OBIO 03-26-2025
- ACRV 03-27-2025
- Dividend Yield
- OBIO N/A
- ACRV N/A
- EPS Growth
- OBIO N/A
- ACRV N/A
- EPS
- OBIO N/A
- ACRV N/A
- Revenue
- OBIO $2,647,000.00
- ACRV N/A
- Revenue This Year
- OBIO $22.61
- ACRV N/A
- Revenue Next Year
- OBIO $16.64
- ACRV N/A
- P/E Ratio
- OBIO N/A
- ACRV N/A
- Revenue Growth
- OBIO N/A
- ACRV N/A
- 52 Week Low
- OBIO $3.96
- ACRV $3.83
- 52 Week High
- OBIO $8.87
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- OBIO 38.59
- ACRV 47.59
- Support Level
- OBIO $5.20
- ACRV $5.00
- Resistance Level
- OBIO $5.98
- ACRV $6.08
- Average True Range (ATR)
- OBIO 0.42
- ACRV 0.64
- MACD
- OBIO -0.07
- ACRV 0.01
- Stochastic Oscillator
- OBIO 2.70
- ACRV 25.68
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.